Merck Strikes Billion-Dollar Deal for Eye Treatment Startup
New York, NY – Pharmaceutical giant Merck has made a significant move in the eye healthcare industry by reaching a $1.3 billion deal to acquire EyeBio, a company specialized in eye-focused drug development. This acquisition is a strategic step for Merck to expand its presence in the ophthalmology sector and enhance its portfolio in treating eye diseases. The deal between Merck and EyeBio is a reflection of the pharmaceutical company’s commitment to investing in innovative …